Review of clinical tumor ablation advance in Asia

Tumor ablation has been widely applied in Asia, accounting for 44.65% of clinical studies worldwide. We reviewed 5853 clinical studies to provide insight on the advance of tumor ablation in Asia chronologically and geographically among different techniques and organs. Since 1998, tumor ablation appl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luo Wang, Jinshun Xu, Jie Yu, Ping Liang
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	tumor ablation radiofrequency ablation microwave ablation percutaneous ethanol injection high-intensity focused ultrasound irreversible electroporation Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/d6637915848c4b1199b001be5a49e1ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d6637915848c4b1199b001be5a49e1ed
record_format	dspace
spelling	oai:doaj.org-article:d6637915848c4b1199b001be5a49e1ed2021-11-17T14:21:55ZReview of clinical tumor ablation advance in Asia0265-67361464-515710.1080/02656736.2021.1983037https://doaj.org/article/d6637915848c4b1199b001be5a49e1ed2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/02656736.2021.1983037https://doaj.org/toc/0265-6736https://doaj.org/toc/1464-5157Tumor ablation has been widely applied in Asia, accounting for 44.65% of clinical studies worldwide. We reviewed 5853 clinical studies to provide insight on the advance of tumor ablation in Asia chronologically and geographically among different techniques and organs. Since 1998, tumor ablation application has dramatically evolved in Asia. All kinds of ablation techniques, including percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation (MWA), laser ablation (LA), cryoablation (CA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE), have been applied, with the first application of PEI and the most popular application of RFA. Twenty-five countries and one district in Asia have applied tumor ablation in various organs, including liver, lung, uterus, thyroid, kidney, pancreas, bone, prostate, breast, adrenal gland, lymph node parathyroid, esophagus, etc. Due to the high incidence of tumors as well as advanced economy and technology, East Asia accounted for 93.87% of studies, led by China (45.00%), Japan (32.72%), South Korea (12.10%), and Taiwan (4.03%). With the enrichment of evidence from large-scale multicenter and randomized control studies, China and South Korea have issued several guidelines on tumor ablation for liver, lung, and thyroid, which provided recommendations for global standardization of tumor ablation techniques. Therefore, Asia has made active contribution to global tumor ablation therapy.Keypoints Key point 1: Asia accounted for 44.65% of clinical studies worldwide on tumor ablation. Key point 2: Twenty-five countries and one district in Asia have used tumor ablation in various organs, and East Asia accounted for 93.87% of studies, led by China (45.00%), Japan (32.72%), South Korea (12.10%), and Taiwan (4.03%). Key point 3: China and South Korea have issued several guidelines on tumor ablation for liver, lung, and thyroid, which provided recommendations for global standardization of tumor ablation techniquesLuo WangJinshun XuJie YuPing LiangTaylor & Francis Grouparticletumor ablationradiofrequency ablationmicrowave ablationpercutaneous ethanol injectionhigh-intensity focused ultrasoundirreversible electroporationMedical technologyR855-855.5ENInternational Journal of Hyperthermia, Vol 38, Iss 1, Pp 1639-1649 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tumor ablation radiofrequency ablation microwave ablation percutaneous ethanol injection high-intensity focused ultrasound irreversible electroporation Medical technology R855-855.5
spellingShingle	tumor ablation radiofrequency ablation microwave ablation percutaneous ethanol injection high-intensity focused ultrasound irreversible electroporation Medical technology R855-855.5 Luo Wang Jinshun Xu Jie Yu Ping Liang Review of clinical tumor ablation advance in Asia
description	Tumor ablation has been widely applied in Asia, accounting for 44.65% of clinical studies worldwide. We reviewed 5853 clinical studies to provide insight on the advance of tumor ablation in Asia chronologically and geographically among different techniques and organs. Since 1998, tumor ablation application has dramatically evolved in Asia. All kinds of ablation techniques, including percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation (MWA), laser ablation (LA), cryoablation (CA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE), have been applied, with the first application of PEI and the most popular application of RFA. Twenty-five countries and one district in Asia have applied tumor ablation in various organs, including liver, lung, uterus, thyroid, kidney, pancreas, bone, prostate, breast, adrenal gland, lymph node parathyroid, esophagus, etc. Due to the high incidence of tumors as well as advanced economy and technology, East Asia accounted for 93.87% of studies, led by China (45.00%), Japan (32.72%), South Korea (12.10%), and Taiwan (4.03%). With the enrichment of evidence from large-scale multicenter and randomized control studies, China and South Korea have issued several guidelines on tumor ablation for liver, lung, and thyroid, which provided recommendations for global standardization of tumor ablation techniques. Therefore, Asia has made active contribution to global tumor ablation therapy.Keypoints Key point 1: Asia accounted for 44.65% of clinical studies worldwide on tumor ablation. Key point 2: Twenty-five countries and one district in Asia have used tumor ablation in various organs, and East Asia accounted for 93.87% of studies, led by China (45.00%), Japan (32.72%), South Korea (12.10%), and Taiwan (4.03%). Key point 3: China and South Korea have issued several guidelines on tumor ablation for liver, lung, and thyroid, which provided recommendations for global standardization of tumor ablation techniques
format	article
author	Luo Wang Jinshun Xu Jie Yu Ping Liang
author_facet	Luo Wang Jinshun Xu Jie Yu Ping Liang
author_sort	Luo Wang
title	Review of clinical tumor ablation advance in Asia
title_short	Review of clinical tumor ablation advance in Asia
title_full	Review of clinical tumor ablation advance in Asia
title_fullStr	Review of clinical tumor ablation advance in Asia
title_full_unstemmed	Review of clinical tumor ablation advance in Asia
title_sort	review of clinical tumor ablation advance in asia
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/d6637915848c4b1199b001be5a49e1ed
work_keys_str_mv	AT luowang reviewofclinicaltumorablationadvanceinasia AT jinshunxu reviewofclinicaltumorablationadvanceinasia AT jieyu reviewofclinicaltumorablationadvanceinasia AT pingliang reviewofclinicaltumorablationadvanceinasia
_version_	1718425512674590720

Review of clinical tumor ablation advance in Asia

Ejemplares similares